AIRISE-X-NP

AIRISE-X-NP is a preclinical-stage therapeutic candidate developed by PDX Pharmaceuticals for the treatment of solid tumors. It is built upon the company's proprietary AIRISE™ (Artificial Intelligence-guided RNAi Selection and Evaluation) platform, which utilizes artificial intelligence to optimize the selection of small interfering RNA (siRNA) sequences for gene silencing. The candidate employs a nanoparticle delivery system (denoted by the 'NP' suffix), likely based on PDX's polymer-grafted nanoparticle technology, designed to protect the siRNA payload from systemic degradation and facilitate targeted delivery to tumor cells. While the specific molecular target of the siRNA in AIRISE-X-NP is currently undisclosed (referred to as 'Target X'), the program is part of a broader pipeline of RNAi-based therapies aimed at addressing difficult-to-treat cancers by silencing oncogenic drivers critical for tumor progression.